Titan Pharmaceuticals Inc. (TTNP)

1.21
0.02 1.70
NASDAQ : Health Technology
Prev Close 1.19
Open 1.19
Day Low/High 1.19 / 1.23
52 Wk Low/High 1.03 / 6.00
Volume 83.57K
Avg Volume 312.90K
Exchange NASDAQ
Shares Outstanding 13.51M
Market Cap 16.48M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Titan Pharmaceuticals Partners With Southside To Further Expand Specialty Pharmacy Network For Probuphine®

Titan Pharmaceuticals Partners With Southside To Further Expand Specialty Pharmacy Network For Probuphine®

SOUTH SAN FRANCISCO, Calif., June 4, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals Reports First Quarter 2019 Financial Results

Titan Pharmaceuticals Reports First Quarter 2019 Financial Results

SOUTH SAN FRANCISCO, Calif., May 15, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals Further Expands Patient Access To Probuphine® Via Product Purchase And Supply Agreement With Express Scripts' Specialty Pharmacy, Accredo®

Titan Pharmaceuticals Further Expands Patient Access To Probuphine® Via Product Purchase And Supply Agreement With Express Scripts' Specialty Pharmacy, Accredo®

SOUTH SAN FRANCISCO, Calif., May 13, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals To Release First Quarter 2019 Financial Results On May 15 - Conference Call To Follow

Titan Pharmaceuticals To Release First Quarter 2019 Financial Results On May 15 - Conference Call To Follow

SOUTH SAN FRANCISCO, Calif., May 8, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals And Molteni Announce Positive EU CHMP Opinion For Probuphine®

Titan Pharmaceuticals And Molteni Announce Positive EU CHMP Opinion For Probuphine®

- Probuphine to be marketed in the European Union under the brand name "Sixmo" -

Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results

Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2018 Financial Results

SOUTH SAN FRANCISCO, Calif., April 1, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals Partners With AppianRx To Provide Comprehensive Probuphine® Patient Support Services

Titan Pharmaceuticals Partners With AppianRx To Provide Comprehensive Probuphine® Patient Support Services

SOUTH SAN FRANCISCO, Calif., March 28, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc.

Titan Pharmaceuticals To Report Fourth Quarter And Full Year 2018 Financial Results On April 1, 2019

Titan Pharmaceuticals To Report Fourth Quarter And Full Year 2018 Financial Results On April 1, 2019

Management Team to Host Conference Call on April 2, 2019 at 8:30 a.m. ET / 5:30 a.m. PT

Titan Pharmaceuticals Reports Positive Initial Results Of Probuphine® Relaunch

Titan Pharmaceuticals Reports Positive Initial Results Of Probuphine® Relaunch

- Double-Digit Increase in Probuphine Shipments -

Titan Pharmaceuticals Announces Reverse Stock Split

Titan Pharmaceuticals Announces Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Jan.

Short Interest Increases 24% For TTNP

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 288,074 share increase in total short interest for Titan Pharmaceuticals Inc , to 1,483,108, an increase of 24.11% since 05/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: HSC, MTLS, PBH, SMCI Downgrades: BURL, CWCO, ELTK, IXYS, PEB, POST, RTIX, TBPH, TISA, TTNP, WMT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

TTNP: Insiders vs. Shorts

TTNP: Insiders vs. Shorts

The most recent short interest data was recently released for the 10/14/2016 settlement date, and Titan Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 12.68 "days to cover" versus the median component at 6.24. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Analysts' Actions -- American Eagle, Mattel, Netflix, Tesaro and More

Analysts' Actions -- American Eagle, Mattel, Netflix, Tesaro and More

Here are Monday's top research calls, including upgrades for American Eagle, Mattel and Tesaro, and new coverage of Netflix.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CVRR, TTNP, WMS Downgrades: DAR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Noteworthy Wednesday Option Activity: TTNP, FCEL, PRLB

Noteworthy Wednesday Option Activity: TTNP, FCEL, PRLB

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Titan Pharmaceuticals Inc , where a total of 4,278 contracts have traded so far, representing approximately 427,800 underlying shares. That amounts to about 262.5% of TTNP's average daily trading volume over the past month of 163,000 shares.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share look ready to break out and trade higher from current levels.

Titan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approval

Titan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approval

Titan Pharmaceuticals (TTNP) stock is climbing after the FDA's Psychopharmacologic Drugs Advisory Committee voted in favor of approving the company's treatment for opioid addiction.

4 Biotech Stocks Under $10 to Trade for Big Breakouts

4 Biotech Stocks Under $10 to Trade for Big Breakouts

These under-$10 biotech stocks are within range of triggering major breakout trades.

Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle

Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle

Titan and its partner will resubmit Probuphine for FDA approval later this year.

TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Potential Breach Of Fiduciary Duty

TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Potential Breach Of Fiduciary Duty

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Titan Pharmaceuticals,...

FDA Rejection of Titan's Probuphine Looks Like a Mugging

FDA Rejection of Titan's Probuphine Looks Like a Mugging

FDA find much at fault with Titan's implantable therapy for opioid dependence.

Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy

Biotech Stock Mailbag: Exact Sciences, Galena, Titan, Arena, Breakthrough Therapy

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Titan Pharma: FDA Panel Live Blog

Titan Pharma: FDA Panel Live Blog

Join TheStreet's Adam Feuerstein for his live blog covering the FDA panel reviewing Titan's treatment for opioid addiction.

The Next Big Thing In Biotech: Titan

The Next Big Thing In Biotech: Titan

Titan Pharmaceuticals is the next big thing in biotech, Adam Feuerstein, Sr. Columnist for TheStreet, tells Gregg Greenberg

Best And Worst FDA Drug Approval Stocks of 2013

Best And Worst FDA Drug Approval Stocks of 2013

Contestants in TheStreet's FDA Drug Approval Contest think well of Sarepta, Navidea and Biogen, less so about Arena, Aveo and Delcath.

Play TheStreet's FDA Drug Approval Contest

Play TheStreet's FDA Drug Approval Contest

Who will be the premier prognosticator of FDA drug approvals in 2013?

TheStreet Quant Rating: D (Sell)